Patent intelligence · US
US 2021387969
BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS
BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS
Patent details — US 2021387969
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 16, 2021
- Expiration
- Dec 11, 2041
- Applicant
- HEPTARES THERAPEUTICS LTD [GB]
- CPC classes
- A61P/2518, A61P/2528
Quick answer
US 2021387969 (BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS) is held by HEPTARES THERAPEUTICS LTD [GB]. Status: granted. Granted Dec 16, 2021. Expires Dec 11, 2041 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- HEPTARES THERAPEUTICS LTD [GB]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P/2518, A61P/2528
More from HEPTARES THERAPEUTICS LTD [GB]
Related pharmaceutical patents in our USPTO index.
-
US 12383545
TREATMENT OF MIGRAINE
granted -
US 2025064788
TREATMENT OF MIGRAINE
granted -
US 2024180883
TREATMENT OF MIGRAINE
granted -
WO 2024081718
ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE
granted -
CA 3244873
TRAITEMENT PRÉVENTIF DE LA MIGRAINE
granted -
WO 2023077094
TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR
granted -
US 2023130736
METHODS OF TREATING MIGRAINE
granted -
US 2022380379
PHARMACEUTICAL COMPOUNDS
granted
Frequently asked questions
What is US patent 2021387969?
US 2021387969 (BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS) is held by HEPTARES THERAPEUTICS LTD [GB]. Status: granted. Granted Dec 16, 2021. Expires Dec 11, 2041 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2021387969?
HEPTARES THERAPEUTICS LTD [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2021387969 expire?
Our index shows an expiration date of Dec 11, 2041 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.